Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2015, Article ID 614736, 8 pages
http://dx.doi.org/10.1155/2015/614736
Clinical Study

Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma

1H. Lee. Moffitt Cancer Center, Tampa, FL 33612, USA
2MD Anderson Cancer Institute, Houston, TX 77030, USA
3The Wistar Institute, Philadelphia, PA 19104, USA
421st Century Oncology, Scottsdale, AZ 85251, USA

Received 27 August 2015; Revised 14 November 2015; Accepted 29 November 2015

Academic Editor: Ajay Puri

Copyright © 2015 Shailaja Raj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. I. Spira and D. S. Ettinger, “The use of chemotherapy in soft-tissue sarcomas,” The Oncologist, vol. 7, no. 4, pp. 348–359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Brennan, E. S. Casper, L. B. Harrison, M. H. Shiu, J. Gaynor, and S. I. Hajdu, “The role of multimodality therapy in soft-tissue sarcoma,” Annals of Surgery, vol. 214, no. 3, pp. 328–336, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. S. A. Rosenberg, J. Tepper, E. Glatstein et al., “The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy,” Annals of Surgery, vol. 196, no. 3, pp. 305–315, 1982. View at Publisher · View at Google Scholar · View at Scopus
  4. P. W. Pisters, L. B. Harrison, D. H. Leung, J. M. Woodruff, E. S. Casper, and M. F. Brennan, “Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 859–868, 1996. View at Google Scholar · View at Scopus
  5. B. Rooser, P. Gustafson, and A. Rydholm, “Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma?” Cancer, vol. 65, no. 8, pp. 1727–1729, 1990. View at Publisher · View at Google Scholar · View at Scopus
  6. J.-M. Coindre, P. Terrier, L. Guillou et al., “Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas,” Cancer, vol. 91, no. 10, pp. 1914–1926, 2001. View at Google Scholar · View at Scopus
  7. J. F. Tierney, “Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data,” The Lancet, vol. 350, no. 9092, pp. 1647–1654, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Frustaci, F. Gherlinzoni, A. De Paoli et al., “Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1238–1247, 2001. View at Google Scholar · View at Scopus
  9. D. Nelson, S. Fisher, and B. Robinson, “The ‘trojan Horse’ approach to tumor immunotherapy: targeting the tumor microenvironment,” Journal of Immunology Research, vol. 2014, Article ID 789069, 14 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Banchereau and R. M. Steinman, “Dendritic cells and the control of immunity,” Nature, vol. 392, no. 6673, pp. 245–252, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Schreibelt, J. Tel, K. H. E. W. J. Sliepen et al., “Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy,” Cancer Immunology, Immunotherapy, vol. 59, no. 10, pp. 1573–1582, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. E. Finkelstein, C. Iclozan, M. M. Bui et al., “Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients,” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 2, pp. 924–932, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Chakraborty, S. I. Abrams, C. N. Coleman, K. Camphausen, J. Schlom, and J. W. Hodge, “External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing,” Cancer Research, vol. 64, no. 12, pp. 4328–4337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Park, C. Yee, and K.-M. Lee, “The effect of radiation on the immune response to cancers,” International Journal of Molecular Sciences, vol. 15, no. 1, pp. 927–943, 2014. View at Publisher · View at Google Scholar
  15. E. Nikitina and D. I. Gabrilovich, “Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer,” International Journal of Cancer, vol. 94, no. 6, pp. 825–833, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz et al., “Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration,” Cancer Research, vol. 63, no. 23, pp. 8466–8475, 2003. View at Google Scholar · View at Scopus
  17. S. Rusakiewicz, M. Semeraro, M. Sarabi et al., “Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors,” Cancer Research, vol. 73, no. 12, pp. 3499–3510, 2013. View at Publisher · View at Google Scholar
  18. P. Brinkrolf, S. Landmeier, B. Altvater et al., “A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease,” International Journal of Cancer, vol. 125, no. 4, pp. 879–886, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Berghuis, S. J. Santos, H. J. Baelde et al., “Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression,” The Journal of Pathology, vol. 223, no. 3, pp. 347–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Pisarev, B. Yu, R. Salup, S. Sherman, D. C. Altieri, and D. I. Gabrilovich, “Full-length dominant-negative survivin for cancer immunotherapy,” Clinical Cancer Research, vol. 9, no. 17, pp. 6523–6533, 2003. View at Google Scholar · View at Scopus
  21. D. C. Altieri, “Validating survivin as a cancer therapeutic target,” Nature Reviews Cancer, vol. 3, no. 1, pp. 46–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk et al., “Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression,” Cancer Research, vol. 61, no. 23, pp. 8513–8519, 2001. View at Google Scholar · View at Scopus
  23. S. E. Finkelstein, T. Carey, I. Fricke et al., “Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma,” Journal of Immunotherapy, vol. 33, no. 8, pp. 817–827, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. W. J. Lesterhuis, I. J. M. De Vries, G. Schreibelt et al., “Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients,” Clinical Cancer Research, vol. 17, no. 17, pp. 5725–5735, 2011. View at Publisher · View at Google Scholar · View at Scopus